-
1 month ago | 
news.bloomberglaw.com | Yiqin Shen |Neil Campling
The escalating tariff fight between the US and China is casting a shadow over one of the world’s biggest pending deals, and traders are growing fearful that the takeover will get bogged down by Beijing’s antitrust regulators. Ansys Inc., which agreed to be bought by chip-designer Synopsys Inc. for about $34 billion back in January 2024, ranks as the world’s sixth-biggest acquisition of the past two years, according to data compiled by Bloomberg.
-
1 month ago | 
bloomberg.com | Yiqin Shen |Neil Campling
Synopsys is one of the few major companies in the world that makes software used to design semiconductors. (Bloomberg) -- The escalating tariff fight between the US and China is casting a shadow over one of the world’s biggest pending deals, and traders are growing fearful that the takeover will get bogged down by Beijing’s antitrust regulators. Ansys Inc., which agreed to be bought by chip-designer Synopsys Inc.
-
2 months ago | 
bloomberg.com | Pablo Mayo Cerqueiro |Neil Campling
Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world For Customers Bloomberg Anywhere Remote Login Software Updates Manage Products and Account Information Support Americas+1 212 318 2000 EMEA+44 20 7330 7500 Asia Pacific+65 6212 1000 Company About Careers Inclusion at Bloomberg Tech at Bloomberg Philanthropy Sustainability Bloomberg London...
-
2 months ago | 
ca.finance.yahoo.com | Pablo Mayo Cerqueiro |Neil Campling
(Bloomberg) -- This year’s unexpected demand for European stocks is helping to drive the region’s largest wave of block sales this century, with bankers anticipating more deals ahead. • None They Built a Secret Apartment in a Mall. Now the Mall Is Dying. • None New York Subway Ditches MetroCard After 32 Years for Tap-And-Go• None Despite Cost-Cutting Moves, Trump Plans to Remake DC in His StyleFrom Pfizer Inc.
-
2 months ago | 
news.bloombergtax.com | Pablo Mayo Cerqueiro |Neil Campling
XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
-
2 months ago | 
news.bloomberglaw.com | Pablo Mayo Cerqueiro |Neil Campling
This year’s unexpected demand for European stocks is helping to drive the region’s largest wave of block sales this century, with bankers anticipating more deals ahead. From Pfizer Inc. finalizing its Haleon Plc exit to governments disposing of their crisis-era stakes in banks, investors have sold nearly $26 billion worth of European stocks through big-ticket trades in 2025, according to data compiled by Bloomberg.
-
Feb 21, 2025 | 
ca.finance.yahoo.com | Lisa Pham |Neil Campling
(Bloomberg) -- GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist investors again. • None Sorry, Kids: Disney’s New York Headquarters Is for Grown-UpsShares in the British drugmaker have fallen about 19% since it spun off its consumer health business in 2022, a move that activists had supported.
-
Feb 21, 2025 | 
bloomberg.com | Lisa Pham |Neil Campling
GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist investors again. Shares in the British drugmaker have fallen about 17% since it spun off its consumer health business in 2022, a move that activists had supported. Analyst sentiment has been turning more negative, as patents for medicines including HIV treatment dolutegravir are set to expire in coming years.
-
Feb 21, 2025 | 
news.bloomberglaw.com | Lisa Pham |Neil Campling
GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist investors again. Shares in the British drugmaker have fallen about 17% since it spun off its consumer health business in 2022, a move that activists had supported. Analyst sentiment has been turning more negative, as patents for medicines including HIV treatment dolutegravir are set to expire in coming years.
-
Feb 21, 2025 | 
news.bloombergtax.com | Lisa Pham |Neil Campling
XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
